← Eichor
Study identifier: NCT05863234 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia

Condition: Aggressive NK Cell Leukemia  ·  Sponsor: Hiroshima University Hospital

PhasePhase 1/Phase 2
Planned participants7
Who can joinAll sexes, 18 Years to 70 Years
Healthy volunteersNo

About this study

This is Phase I/II Dose-Escalation Study to evaluate the tolerability, safety, efficacy and pharmacokinetics of PPMX-T003 in aggressive NK-cell leukemia.

This description comes directly from the study's public registry record.

Talk to the study team

Kiyoshi Ando  ·  +81 82-257-5555  ·  andok@keyaki.cc.u-tokai.ac.jp

Always discuss trial participation with your own doctor first.

Locations (1)

Hiroshima University HospitalHiroshima, Hiroshima, JapanRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05863234